This document addresses three of the TGA (Therapeutic Goods Administration) 2025 consultation questions:
1. Contraindications for medical cannabis – see Appendix A
2. Claims for medical cannabis not supported by rigorous science – See Appendix B
3. Lack of quality assurance in the production of medicinal cannabis – See Appendix C